Study Title
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Study Number
SCRI C6461001
Enrollment status
Open
Categories
1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence, Lung Cancer, Non-Small Cell Lung Cancer
Study Summary
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
Study Coordinator(s)
- Navigator Heather, 309-243-3661 hthulean@illinoiscancercare.com
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
Study Link
View Study DetailsAdditional Information
Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washington